BioLine Rx Ltd (BLRX)

0.85
0.00 0.24
NASDAQ : Health Care
Prev Close 0.85
Open 0.85
Day Low/High 0.83 / 0.86
52 Wk Low/High 0.71 / 2.25
Volume 333.43K
Avg Volume 506.50K
Exchange NASDAQ
Shares Outstanding 95.61M
Market Cap 81.27M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioLineRx Announces Acquisition Of Agalimmune Ltd. To Accelerate Expansion Of Immuno-Oncology Pipeline

Agalimmune's Lead Asset, AGI-134, Provides a Unique Approach for Eliciting Patient-specific, Anti-tumor Immune Responses in Multiple Cancer Types

BioLineRx To Report Annual 2016 Results On March 23, 2017

Management to hold a conference call at 9:00 a.m. EDT

BioLineRx Announces Initiation Of Immuno-Oncology Phase 2 Study To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer

BioLineRx Announces Initiation Of Immuno-Oncology Phase 2 Study To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer

Study is part of strategic research collaboration between MSD and MD Anderson Cancer Center aimed to evaluate KEYTRUDA in selected GI tumors using various combinations

BioLineRx In-licenses Novel Anti-Inflammatory Treatment For Dry Eye Syndrome Under Strategic Collaboration With Major Global Pharmaceutical Company

BioLineRx In-licenses Novel Anti-Inflammatory Treatment For Dry Eye Syndrome Under Strategic Collaboration With Major Global Pharmaceutical Company

Therapeutic compound is third project in-licensed under strategic collaboration with Novartis for screening and development of novel drug candidates

BioLineRx To Report Third Quarter Results On November 22, 2016

BioLineRx To Report Third Quarter Results On November 22, 2016

Management to hold conference call at 10:00 a.m. EST

BioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement

BioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement

BioLineRx (BLRX) signed a licensing agreement with two Israeli companies to allow the development of a drug that treats liver failure conditions.

BioLineRx Announces In-licensing Of Novel Treatment For Liver Failure Conditions Under Strategic Collaboration

BioLineRx Announces In-licensing Of Novel Treatment For Liver Failure Conditions Under Strategic Collaboration

Therapeutic compound is second project in-licensed under strategic collaboration with Novartis for screening and development of novel drug candidates

BioLineRx Ltd. Presents Corporate Objectives At Investor Breakfast Meeting In NY

BioLineRx Ltd. Presents Corporate Objectives At Investor Breakfast Meeting In NY

- Presentation includes details of 2017 operating plan and five-year Company vision -

BioLineRx Presents Final Results From Phase 2a Trial For Relapsed/Refractory AML At SOHO Conference

BioLineRx Presents Final Results From Phase 2a Trial For Relapsed/Refractory AML At SOHO Conference

Combination of BL-8040 with Ara-C in difficult-to-treat patient population demonstrated substantial improvement over clinical response rates historically achieved with Ara-C

BioLineRx Announces Clinical Research Collaboration To Investigate Combination Of BL-8040 With Atezolizumab In Multiple Oncology Indications

BioLineRx Announces Clinical Research Collaboration To Investigate Combination Of BL-8040 With Atezolizumab In Multiple Oncology Indications

Cancer immunotherapy collaboration with Genentech includes several Phase 1b combination studies for multiple solid tumor indications and AML

BioLineRx And I-Bridge Capital Establish A New Drug Development Joint Venture In China

BioLineRx And I-Bridge Capital Establish A New Drug Development Joint Venture In China

JV will promote development and commercialization of Israeli-sourced therapeutic assets for Chinese healthcare market

BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer

BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer

- Phase 2 study is part of strategic clinical research collaboration between MSD and MD Anderson Cancer Center aimed at evaluating KEYTRUDA in selected GI tumors using various combinations -

BioLineRx To Report Second Quarter Results On August 11, 2016

BioLineRx To Report Second Quarter Results On August 11, 2016

Management to hold conference call at 10:00 a.m. EDT